Drugs /

tavolimab

Back to Drugs List

Overview

Generic Name(s):
tavolimab
NCI Definition [1]:
An agonistic, humanized monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, tavolimab selectively binds to and activates the OX40 receptor. OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this agent may promote an immune response against TAAs-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.

Clinical Trials

View Clinical Trials for tavolimab

Tavolimab has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating tavolimab, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

Fallopian tube carcinoma, fallopian tube carcinosarcoma, and fallopian tube undifferentiated carcinoma are the most common diseases being investigated in tavolimab clinical trials [2].

Drug Details

Synonyms [2]:
anti-ox40 monoclonal antibody medi0562, tavolixizumab, medi0562, medi-0562
Drug Target(s) [2]:
TNFRSF4
NCIT ID [1]:
C120041

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.